Page last updated: 2024-11-13

dcg 04

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

DCG 04: E-64 analog; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71296083
MeSH IDM0377597

Synonyms (9)

Synonym
CD-892 ,
n-[3-(ethoxycarbonyl)oxirane-2-carbonyl]-l-leucyl-n-(6-{[(2s)-1-amino-1-oxo-6-{[5-(2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)pentanoyl]amino}hexan-2-yl]amino}-6-oxohexyl)-l-tyrosinamide
DTXSID60744271
dcg-04
ethyl 3-[[(2s)-1-[[(2s)-1-[[6-[[(2s)-1-amino-1-oxo-6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexan-2-yl]amino]-6-oxohexyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-c
ethyl 3-(((4s,7s,17s)-17-carbamoyl-7-(4-hydroxybenzyl)-2-methyl-5,8,15,23-tetraoxo-27-(2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)-6,9,16,22-tetraazaheptacosan-4-yl)carbamoyl)oxirane-2-carboxylate
dcg 04
cd 892
cd892
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (71.43)29.6817
2010's2 (14.29)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]